Kura Oncology, Inc. $KURA Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 214.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,715 shares of the company’s stock after buying an additional 103,411 shares during the period. SG Americas Securities LLC owned 0.17% of Kura Oncology worth $1,576,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of KURA. Assenagon Asset Management S.A. lifted its position in Kura Oncology by 37.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company’s stock valued at $11,196,000 after acquiring an additional 345,951 shares during the last quarter. Sector Gamma AS purchased a new position in shares of Kura Oncology during the third quarter worth about $3,880,000. Nan Fung Trinity HK Ltd. purchased a new position in shares of Kura Oncology during the third quarter worth about $2,043,000. CWM LLC increased its position in shares of Kura Oncology by 185.9% during the third quarter. CWM LLC now owns 118,363 shares of the company’s stock worth $1,048,000 after purchasing an additional 76,957 shares in the last quarter. Finally, EcoR1 Capital LLC increased its position in shares of Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after purchasing an additional 1,559,702 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KURA. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Wall Street Zen downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Wedbush lowered their target price on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Finally, UBS Group reaffirmed a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.86.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.49 on Tuesday. The firm has a market cap of $749.92 million, a P/E ratio of -2.67 and a beta of 0.25. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $12.49. The business’s 50-day moving average price is $8.39 and its 200 day moving average price is $9.49. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.20). Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. The company had revenue of $17.34 million for the quarter, compared to analysts’ expectations of $34.71 million. On average, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Brian T. Powl sold 6,414 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $54,262.44. Following the completion of the sale, the insider owned 183,275 shares in the company, valued at $1,550,506.50. This represents a 3.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 8,180 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the sale, the insider directly owned 267,274 shares of the company’s stock, valued at approximately $2,261,138.04. This represents a 2.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 36,068 shares of company stock worth $305,135. 6.40% of the stock is currently owned by company insiders.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.